中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2008年
21期
8-9
,共2页
曲美他嗪%心力衰竭%缺血性心脏病
麯美他嗪%心力衰竭%缺血性心髒病
곡미타진%심력쇠갈%결혈성심장병
Trimetazidine%Congestive heart failure%Ischemic heart disease
目的 观察曲美他嗪(TMZ)治疗缺血性心脏病慢性心力衰竭(CHF)患者的临床疗效.方法 选择缺血性心脏病慢性心力衰竭患者94例,随机分为两组:对照组49例常规给予洋地黄、利尿剂、血管扩张剂、ACEI或ARB、B-受体阻滞荆等药物;曲美他嗪组45例,在常规药物治疗的基础上加用曲美他嗪(TMZ)20 ms/d,3次/d,6个月后观察再住院率及心功能改善情况.结果 ①随访6个月曲美他嗪组死亡2例(4.44%),对照组死亡5例(10.20%),两组比较差异无统计学意义;曲美他嗪组再住院8例(17.78%),对照组再住院18例(36.73%),两组比较差异有统计学意义(P<0.05);②存活的87例患者最终进入结果分析,曲关他嗪组43例,对照组44例,两组在性别、年龄、合并症、用药情况等方面比较差异无统计学意义,治疗6 min步行试验步行距离6个月后,曲美他嗪组心功能改善总有效率显著优于对照组(81.40%vs 61.36%,P<0.05);③两组心率均显著降低,6-MT,显著提高,且曲美他嗪组显著优于对照组(521±31 vs425±23,P<0.05).结论 曲美他嗪治疗心力衰竭可降低患者再住院率,改善心功能,提高活动耐力.
目的 觀察麯美他嗪(TMZ)治療缺血性心髒病慢性心力衰竭(CHF)患者的臨床療效.方法 選擇缺血性心髒病慢性心力衰竭患者94例,隨機分為兩組:對照組49例常規給予洋地黃、利尿劑、血管擴張劑、ACEI或ARB、B-受體阻滯荊等藥物;麯美他嗪組45例,在常規藥物治療的基礎上加用麯美他嗪(TMZ)20 ms/d,3次/d,6箇月後觀察再住院率及心功能改善情況.結果 ①隨訪6箇月麯美他嗪組死亡2例(4.44%),對照組死亡5例(10.20%),兩組比較差異無統計學意義;麯美他嗪組再住院8例(17.78%),對照組再住院18例(36.73%),兩組比較差異有統計學意義(P<0.05);②存活的87例患者最終進入結果分析,麯關他嗪組43例,對照組44例,兩組在性彆、年齡、閤併癥、用藥情況等方麵比較差異無統計學意義,治療6 min步行試驗步行距離6箇月後,麯美他嗪組心功能改善總有效率顯著優于對照組(81.40%vs 61.36%,P<0.05);③兩組心率均顯著降低,6-MT,顯著提高,且麯美他嗪組顯著優于對照組(521±31 vs425±23,P<0.05).結論 麯美他嗪治療心力衰竭可降低患者再住院率,改善心功能,提高活動耐力.
목적 관찰곡미타진(TMZ)치료결혈성심장병만성심력쇠갈(CHF)환자적림상료효.방법 선택결혈성심장병만성심력쇠갈환자94례,수궤분위량조:대조조49례상규급여양지황、이뇨제、혈관확장제、ACEI혹ARB、B-수체조체형등약물;곡미타진조45례,재상규약물치료적기출상가용곡미타진(TMZ)20 ms/d,3차/d,6개월후관찰재주원솔급심공능개선정황.결과 ①수방6개월곡미타진조사망2례(4.44%),대조조사망5례(10.20%),량조비교차이무통계학의의;곡미타진조재주원8례(17.78%),대조조재주원18례(36.73%),량조비교차이유통계학의의(P<0.05);②존활적87례환자최종진입결과분석,곡관타진조43례,대조조44례,량조재성별、년령、합병증、용약정황등방면비교차이무통계학의의,치료6 min보행시험보행거리6개월후,곡미타진조심공능개선총유효솔현저우우대조조(81.40%vs 61.36%,P<0.05);③량조심솔균현저강저,6-MT,현저제고,차곡미타진조현저우우대조조(521±31 vs425±23,P<0.05).결론 곡미타진치료심력쇠갈가강저환자재주원솔,개선심공능,제고활동내력.
Objective To observe the cardiac functional effect of TMZ on the patients of chronic heart failure (CHF) with is-chemic heart disease. Methods Choose 94 eases of CHF with isebemie heart disease, divided into two groups randomly: control group (CG) 49 cases received routine treatment ( digitalis, diuretics, vasodilator, ACEI or ARB, β-blocker, ect ) ; group of TMZ(TG)45 eases received TMZ (20 mg/d,3/d) for 6 months on the basis of routine therapy,then observe the conditions of readmis-sion rate(RER)and the improvement of heart fumction.Results ①Follow up for 6 months ,the death of TG was 2 case (4.44%),the death of CG was 5 case (10. 20%) ,and there was no significant in two groups;RER of TG was 8 case (17.78%) ,RER of CG was 18 case (36.73%),and there was great significant in two groups (P<0.05);② 87 cases was survived including CG 44 cases and TG 43 cases come into the result analysis,between which there was no significant in gender,age,risk factors and complication before treatment. The total effective rate of the improvement of heart function of TG was higher than CG (81.40% vs 61.36%,P<0.05).③ HR of the both groups cut down significantly ,and both 6-MT elevate significantly in which TG was higher than CG (521±31 vs 425.94±23, P<0.05). Conclusion The treatment of heart failure by TMZ can depresss the readmission rate, im-prove the heart function and elevate the active endurance.
